Pharmacy's Compounding Resembles Rx Manufacturing Operation, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA "warning letter" states that Lincare and Reliant Pharmacy produce "essentially copies of commercially available drugs" without documented patient-specific medical need. This practice goes beyond the scope of traditional compounding, the letter states.
You may also be interested in...
FDA Cracks Down On Three Pharmacies Compounding Inhalation Drugs
In warning letters to the pharmacies, FDA says their compounding of mass amounts of drugs goes “well beyond” traditional compounding.
FDA Cracks Down On Three Pharmacies Compounding Inhalation Drugs
In warning letters to the pharmacies, FDA says their compounding of mass amounts of drugs goes “well beyond” traditional compounding.
FDA Cites Respi Care As Part Of Pharmacy Compounding Enforcement
The agency issues its second “warning letter” in a month citing a pharmacy’s compounding operations as comparable to that of a drug manufacturer. The agency also notes cGMP violations observed during an inspection of Respi Care’s facility in Puerto Rico.